Gustavo Alva, MD, DFAPA

Clinicians outline ways to boost schizophrenia outcomes: team-and-family collaboration, early detection, medication access, measurement-based care.

New rapid-acting and long-acting injectables help bridge hospital-to-community care, cutting post-discharge nonadherence and relapse risk.

Clinicians weigh telepsychiatry for schizophrenia, urge early long-acting injectables, and reveal tips on samples, coupons, and prior authorizations.

Inside the ED psychiatric crisis pathway: rapid evaluation, safety triage, long-acting injectables,

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.

Where can vagus nerve stimulation fit into treating depression?

Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.

Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.

Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.

Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.

Expert explores fast-acting depression treatments, psilocybin trial pitfalls, and why stigma still limits buprenorphine access for opioid use disorder.

This episode, titled "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," features panelist Mark Jankelow discussing the practical clinical considerations surrounding a novel muscarinic agent.

Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.

Expert shares ADHD medication sequencing tips and practical insomnia strategies, from stimulants to melatonin, for kids and adults.

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.

Psychiatrist Gus Alva highlights new depression therapies, neuromodulation, and why screening for bipolar disorder prevents antidepressant harm.

Psychiatrists share women who inspire them for Women's History Month.

Gus Alva, MD, shares the importance of proper recognition of stuttering among patients.

Conferences: the perfect networking opportunity.

Panelists discuss how increasing patient comfort with technology and advances in artificial intelligence (AI) and virtual reality (VR) create opportunities for integrating prescription digital therapeutics (PDTs) into schizophrenia care, while emphasizing the need for clinician education and preserving the human connection.

Panelists discuss patient hesitations toward prescription digital therapeutics (PDTs) for schizophrenia. They highlight concerns about repetitive content and technology mistrust due to symptoms such as paranoia, the significant access barriers related to insurance coverage especially for vulnerable populations, and the critical need for improved clinician education to increase awareness and integration of PDTs into treatment plans.

Panelists discuss the flexible use of prescription digital therapeutics (PDTs) in schizophrenia, comparing them with gym workouts that can be used regularly for maintenance or intensified during symptom flare-ups. They highlight PDTs’ role in addressing negative symptoms, supporting sustained improvement, and offering personalized, ongoing care alongside medication.